Aster Capital Management’s LENZ Therapeutics LENZ Stock Holding History

Aster Capital Management’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-323	Closed	-$5.17K	–	1403
2025 Q4	$5.17K	Buy	+323	New	+$9.41K	﹤0.01%	864
2025 Q1	–	Sell	-278	Closed	-$8.03K	–	1723
2024 Q4	$8.03K	Buy	+278	New	+$8.47K	﹤0.01%	802

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Aster Capital Management's LENZ Position: Q1 2026 in Review

Aster Capital Management sold out of LENZ Therapeutics (LENZ) in Q1 2026, closing a stake of 323 shares — an estimated $5.17K sold.

Aster Capital Management first reported a position in LENZ in Q4 2024 and held it in 2 quarters. The position peaked at $8.03K in Q4 2024. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

Aster Capital Management reported no remaining LENZ Therapeutics position as of Q1 2026 after selling out during the quarter.
Aster Capital Management sold 323 LENZ Therapeutics shares in Q1 2026, an estimated $5.17K.
Aster Capital Management first reported a position in LENZ Therapeutics in Q4 2024 and held it in 2 quarters.
Aster Capital Management's LENZ Therapeutics position peaked at $8.03K in Q4 2024.
145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Aster Capital Management's 13F filing for Q1 2026, filed 13 May 2026.